"Designing Growth Strategies is in our DNA"

Anticholinergic Drug Market Size, Share, and Industry Analysis, By Type (Natural Alkaloids, Semisynthetic Derivatives, Synthetic Compounds, and Others), By Product Type (Prescription and Over-the-counter (OTC)), By Route of Administration (Oral and Parenteral), By Indication (Parkinson's Disease, Overactive Bladder (OAB) and Urinary Incontinence, Chronic Obstructive Pulmonary Disease (COPD), and Others), By Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Region :Global | Report ID: FBI110469 | Status : Ongoing

 

KEY MARKET INSIGHTS

The anticholinergic drug market is witnessing significant growth due to several key factors, such as technological advancements in the drug manufacturing process, the increasing prevalence of chronic diseases, the aging population, and growing awareness of potential benefits associated with these products. Such factors are driving the demand for anticholinergic drugs, increasing their adoption globally.



  • For instance, according to an article published by Healthline Media in January 2024, anticholinergics can treat various health conditions, including urinary incontinence, chronic obstructive pulmonary disease (COPD), insomnia, and certain types of poisoning. Such widespread use of anticholinergics is anticipated to boost their demand in the forthcoming years, driving the market growth.


Anticholinergic Drug Market Driver


Increasing Prevalence of Chronic Diseases Boosts the Market Growth

The rising prevalence of chronic conditions such as chronic obstructive pulmonary disease (COPD), Parkinson's disease, overactive bladder, and spasmodic gut disorders is driving the demand for anticholinergic drugs. These conditions are well-managed by various anticholinergic drugs along with  potential benefits. Such a scenario is expected to boost their adoption and propel market growth in the coming years.


  • For instance, in August 2023, the World Health Organization (WHO) reported that the prevalence of Parkinson's disease has doubled in the past 25 years.


Request a Free sample to learn more about this report.


The U.S. accounted for an estimated 90,454 Parkinson’s disease cases in 2023, witnessing a growth of 0.5% compared to 2022.

Anticholinergic Drug Market Restraint


Adverse Effects and Product Recalls May Hinder the Market Growth

Anticholinergic drugs are associated with a range of side effects, including cognitive impairment, dry mouth, constipation, urinary retention, and blurred vision. These side effects can be particularly problematic for elderly patients, who are more susceptible to anticholinergic toxicity due to age-related changes in pharmacodynamics and pharmacokinetics. Moreover, product recalls due to the risk of certain medical conditions, such as dementia and cancer associated with anticholinergic long-term use, are expected to hinder the market growth.


  • For instance, in March 2022, Sandoz issued a voluntary recall of 13 lots of the drug orphenadrine citrate 100mg ER tablets due to the presence of nitrosamine, a carcinogen that increases the risk of cancer. This carcinogen was found in the drug at levels greater than the acceptable daily intake (ADI).


Anticholinergic Drug Market Opportunity


Technological Advancements in Drug Development and Pharmaceutical Manufacturing

In recent years, there has been a surge in technological advancements in drug development and pharmaceutical manufacturing. Some of these advancements include adopting advanced technologies such as 3D printing, artificial intelligence (AI) and machine learning (ML) sensors, the Internet of Things (IoT), and smart manufacturing. These technologies are anticipated to enable the production of more effective and safer anticholinergic medications, driving market growth in the near future.


  • For instance, as of July 2024, an article published by Advanced Technology Services, Inc. reported that the integration of IoT in pharmaceutical manufacturing helps manufacturers improve maintenance as well as operational performance.


Segmentation






















By Type


By Product Type


By Route of Administration


By Indication


By Distribution Channel


By Geography



  • Natural Alkaloids

  • Semisynthetic Derivatives

  • Synthetic Compounds

  • Others




  • Prescription

  • Over-the-counter (OTC)




  • Oral

  • Parenteral




  • Parkinson's Disease

  • Overactive Bladder (OAB) and Urinary Incontinence

  • Chronic Obstructive Pulmonary Disease (COPD)

  • Others




  • Hospital Pharmacies

  • Drug Stores & Retail Pharmacies

  • Online Pharmacies




  • North America (U.S. and Canada)

  • Europe (U.K., Germany, France, Spain, Italy, Scandinavia, and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of APAC)

  • Latin America (Brazil, Mexico, and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)



Key Insights


The report covers the following key insights:


  • Prevalence of Key Diseases, By Key Countries, 2023

  • New Product Launches, By Key Players

  • Pipeline Analysis, By Key Players

  • Regulatory Scenario, By Key Countries/Region

  • Key Industry Developments (Mergers, Acquisition, and Partnerships, etc.)

  • Impact of COVID-19 on the Market


Analysis by Type


Based on type, the market is segmented into natural alkaloids, semisynthetic derivatives, synthetic compounds, and others.

The synthetic compounds segment is expected to hold a major share of the global market. This growth can be attributed to the widespread indications and significant number of drugs of these compounds. Such a scenario is projected to stimulate the key players to increase the availability of such drugs, driving the segment growth in the coming years.


  • For instance, as of July 2024, Government Medical College & Hospital has classified synthetic compounds to include mydriatic drugs, antisecretory-antispasmodics, antiparkinsonian, tricyclic antidepressants, phenothiazines, and others.


Analysis By Product Type


By product type, the market is categorized into prescription and over-the-counter (OTC).

The prescription segment accounted for the largest share of the market. The segment’s growth can be attributed to the large number of medical conditions treated by anticholinergics under the supervision of physicians. Moreover, the drugs for a majority of anticholinergic conditions, due to their high potency, are mandated to be sold with a doctor’s prescription only. This is increasing the demand for prescription, which is projected to propel the segment growth.


  • For instance, according to an article published by Healthline Media in January 2024, anticholinergic drugs such as atropine, cyclopentolate, benztropine mesylate, and others are sold under prescription.


Analysis by Route of Administration


By route of administration, the market is divided into oral and parenteral.

The parenteral segment held a substantial share of the anticholinergic drug market in 2023. The growth can be attributed to the greater bioavailability and rapid action of parenteral drugs compared to oral. This is increasing their preference in treating severe conditions, which is anticipated to fuel the segment growth.


  • For instance, according to an article published by the National Center for Biotechnology Information (NCBI) in May 2023, atropine is available in intravenous and intramuscular dosage forms. This drug can be used for the treatment of mushroom poisoning, treatment of diarrhea as second-line therapy, and others.


Analysis by Indication


By indication, the market is divided into Parkinson's disease, overactive bladder (OAB) and urinary incontinence, chronic obstructive pulmonary disease (COPD), and others.

The Parkinson’s disease segment accounted for a significant share of the anticholinergic drug market in 2023. The segment growth can be attributed to the use of anticholinergic drugs as the primary treatment for Parkinson’s disease. Anticholinergic drugs were the first pharmacological agents available for this condition and continue to be utilized, particularly for managing symptoms such as tremors. Common anticholinergic medications such as trihexyphenidyl and benztropine help counteract the imbalance of neurotransmitters in the brain associated with Parkinson's.


  • For instance, as of July 2024, COGENTIN (benztropine mesylate) is being used for the management of Parkinson’s disease.


Analysis by Distribution Channel


By distribution channel, the market is subdivided into hospital pharmacies, drug stores & retail pharmacies, and online pharmacies.

The online pharmacies segment is projected to grow substantially due to the rising preference of patients purchasing anticholinergic drugs from online pharmacies. Moreover, the shift in preference is being influenced by discounts offered by online pharmacies for both prescription and OTC drugs. Such a scenario is expected to fuel the segment growth during the forecast period.


  • For instance, as of July 2024, Apollo Pharmacy is offering ipratropium bromide respules at a discounted price and a cashback offer.


Regional Analysis


To gain extensive insights into the market, Request for Customization


Based on region, the market has been studied across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.

North America accounted for the largest share of the global anticholinergic drug market in 2023. The regional growth is attributed to an increase in the diagnosis of COPD and asthma. This is driving the demand for anticholinergic drugs such as ipratropium bromide, which is expected to boost the market growth.


  • For instance, according to the American Lung Association, 11.7 million people, or 4.6% of adults in the U.S., reported a diagnosis of COPD (chronic obstructive pulmonary disease), chronic bronchitis, or emphysema in 2022.


Europe is the second-largest market based on the demand for anticholinergic drugs. The growth can be attributed to the presence of key players ensuring the high availability of anticholinergic drugs, contributing to their penetration in the region.

The Asia Pacific market is expected to grow substantially over the forthcoming years. The region’s growth can be attributed to the rising aging population, which is more susceptible to chronic diseases. Moreover, rising awareness of such diseases in the region is also expected to fuel the demand for anticholinergic drugs, propelling the regional growth.

Key Players Covered


The global anticholinergic drug market is fragmented, with a large number of companies offering various anticholinergic drugs.

The report includes the profiles of the following key players:


  • Pfizer Inc. (U.S.)

  • Sanofi (France)

  • Casper Pharma (India)

  • GSK plc (U.K.)

  • Novartis AG (Switzerland)

  • Johnson & Johnson Services, Inc. (U.S.)

  • Astellas Pharma Inc. (Japan)

  • Viatris Inc. (U.S.)

  • Teva Pharmaceutical Industries Ltd. (Israel)

  • Macleods Pharmaceuticals Ltd. (India)


Key Industry Developments



  • In January 2024, Defender Pharmaceuticals received a Complete Response Letter (CRL) from the FDA for its New Drug Application (NDA) for intranasal scopolamine (DPI-386) for the prevention of nausea and vomiting induced by motion in adults.

  • In August 2022, American Regent, Inc. launched Atropine Sulfate Injection for temporary blockade of severe or life-threatening muscarinic effects.





  • Ongoing
  • 2024
  • 2019-2023
Consulting Services
    How will you benefit from our consulting services ?
Healthcare Clients
Siemens
National Institutes of Health (NIH)
Olympus
Mindray
Allergan